Insights

Platform Expansion Cellectricon recently launched neurotoxicity testing, extending its neuroscience discovery services into early safety assessment. This creates a timely opportunity to offer complementary tools, technologies, or services that help strengthen and scale its expanded screening capabilities.

Model Manufacturing Its partnership with CCRM Nordic focuses on scalable, reproducible manufacturing of complex cell models. Business development teams can explore needs in cell model production, process development, quality systems, automation, and technologies that support consistent assay performance.

Japan Growth Appointing a Head of Japan Business Development signals investment in the Japanese life sciences market. Potential opportunities include local partnerships, market access support, scientific collaborations, and services that help build customer relationships in the region.

Research Partnerships Cellectricon works with organizations such as the FamilieSCN2A Foundation and Karolinska Institutet on disease-focused research and humanized in vitro methods. These collaborations suggest openness to specialized technologies, research partnerships, and services that accelerate assay development and therapeutic programs.

Lean Operations With 11 to 50 employees and reported revenue below $1 million, Cellectricon may value cost effective solutions that improve productivity without requiring substantial internal infrastructure. Its broad neuroscience platform and sustainability commitments also create potential demand for scalable operational tools and suppliers aligned with responsible business practices.

Similar companies to Cellectricon

Cellectricon Tech Stack

Cellectricon uses 8 technology products and services including iCIMS, WordPress, Cookiebot, and more. Explore Cellectricon's tech stack below.

Media & News

Cellectricon's Email Address Formats

Cellectricon uses at least 4 email formats:
Cellectricon Email FormatsExamplePercentage
First.Last@cellectricon.comJohn.Doe@cellectricon.com
74%
First.MiddleLast@cellectricon.comJohn.MichaelDoe@cellectricon.com
10%
Last@cellectricon.comDoe@cellectricon.com
11%
F.Last@cellectricon.comJ.Doe@cellectricon.com
5%

Frequently Asked Questions

What is Cellectricon's phone number?

Minus sign iconPlus sign icon
You can contact Cellectricon's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Cellectricon's official website and social media links?

Minus sign iconPlus sign icon
Cellectricon's official website is cellectricon.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Cellectricon generate?

Minus sign iconPlus sign icon
As of October 2026, Cellectricon's annual revenue is estimated to be <$1M.

What is Cellectricon's SIC code and NAICS code?

Minus sign iconPlus sign icon
Cellectricon's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cellectricon have currently?

Minus sign iconPlus sign icon
As of October 2026, Cellectricon has approximately 26 employees across 2 continents, including Europe and North America. Key team members include Chief Executive Officer: M. K., Cbo: P. K. and Chief Operating Officer: L. A. Explore Cellectricon's employee directory with LeadIQ.

What industry does Cellectricon belong to?

Minus sign iconPlus sign icon
Cellectricon operates in the Biotechnology Research industry.

What technology does Cellectricon use?

Minus sign iconPlus sign icon
Cellectricon's tech stack includes iCIMS, WordPress, Cookiebot, Shopify, Microsoft 365, core-js, Brevo and Piwik PRO Core.

What is Cellectricon's email format?

Minus sign iconPlus sign icon
Cellectricon's email format typically follows the pattern of First.Last@cellectricon.com. Find more Cellectricon email formats with LeadIQ.

How much funding has Cellectricon raised to date?

Minus sign iconPlus sign icon
As of October 2026, Cellectricon has raised $14M in funding. The last funding round occurred on May 26, 2004 for $7M.

When was Cellectricon founded?

Minus sign iconPlus sign icon
Cellectricon was founded in 2001.
Cellectricon logo

Cellectricon

Biotechnology ResearchVästra Götaland, Sweden11-50 Employees

Cellectricon, based in Mölndal, Västra Götaland, Sweden, specializes in neuroscience drug discovery by delivering highly customized in vitro neurobiology services with a commitment to scientific excellence and quality. The company operates a broad platform that enables the creation of complex disease models and assays for functional and morphological screening, combining drug-discovery know-how with disease-area expertise. Its service modules address Neuroinflammation, Peripheral Neuropathies, Neurodegeneration, and Neuroplasticity, supporting early target and lead-discovery programs. The organization aims to accelerate early R&D, shorten time to decision, and provide novel disease biology insights that help identify targets and lead compounds with potential to yield first-in-class medicines for its clients. In November 2025, Cellectricon integrated with CCRM Nordic AB to expand scalable manufacturing approaches for complex cell models used in early drug discovery and safety testing.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2001
Employees
11-50

Section iconFunding & Financials

  • $14M

    Cellectricon has raised a total of $14M of funding over 3 rounds. Their latest funding round was raised on May 26, 2004 in the amount of $7M as a Series B.

  • <$1M

    Cellectricon's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.